Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRINITY-like phase 3 non-inferiority study of CHF 5993 versus fluticasone furoate/vilanterol plus tiotropium in COPD
2014-001487-35Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium, fluticasone propionate + vilanterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in St. George's Respiratory Questionnaire total score at 26 weeks. Started Dec 2014; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumfluticasone propionate + vilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-001487-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001487-35.